{
    "Trade/Device Name(s)": [
        "Dexcom G6 Continuous Glucose Monitoring (CGM) System",
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System",
        "Dexcom G6 Professional Continuous Glucose Monitoring (CGM) System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K221259",
    "Predicate Device Reference 510(k) Number(s)": [
        "K201328",
        "K203089",
        "K191833"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "QDK",
        "QII"
    ],
    "Summary Letter Date": "April 29, 2022",
    "Summary Letter Received Date": "May 2, 2022",
    "Submission Date": "July 26, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 sensor/applicator",
        "Dexcom G6 BLE transmitter",
        "Mobile application",
        "Receiver"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy (BLE) data transmission"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Mobile application",
        "Accessory",
        "Adhesive patch"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Continuous Glucose Monitoring systems with updated adhesive patch for diabetes management in persons age 2+ years",
    "Indications for Use Summary": "Indicated for real-time continuous glucose monitoring for diabetes management in persons age 2+ years, replacing fingerstick blood glucose testing, aiding in detection of hyperglycemia/hypoglycemia, usable alone or with digitally connected devices including automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}